within Pharmacolibrary.Drugs.ATC.J;

model J04AB30
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J04AB30</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Capreomycin is a cyclic peptide antibiotic used for the treatment of multidrug-resistant tuberculosis (MDR-TB), usually as a second-line agent in combination therapy. It is not approved for first-line use, and due to its toxicity and the advent of newer antituberculotic drugs, its use today is limited.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for typical adult patients after a single intramuscular dose.</p><h4>References</h4><ol><li><p>Garcia-Contreras, L, et al., &amp; Hickey, AJ (2012). Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs. <i>Antimicrobial agents and chemotherapy</i> 56(5) 2612–2618. DOI:<a href=\"https://doi.org/10.1128/AAC.06145-11\">10.1128/AAC.06145-11</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22330920/\">https://pubmed.ncbi.nlm.nih.gov/22330920</a></p></li><li><p>Cambronero-Rojas, A, et al., &amp; Gómez-Gaete, C (2015). Capreomycin oleate microparticles for intramuscular administration: Preparation, in vitro release and preliminary in vivo evaluation. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 209 229–237. DOI:<a href=\"https://doi.org/10.1016/j.jconrel.2015.05.001\">10.1016/j.jconrel.2015.05.001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25956458/\">https://pubmed.ncbi.nlm.nih.gov/25956458</a></p></li><li><p>Shao, Z, et al., &amp; Lam, JKW (2021). Spray-Dried Powder Formulation of Capreomycin Designed for Inhaled Tuberculosis Therapy. <i>Pharmaceutics</i> 13(12) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics13122044\">10.3390/pharmaceutics13122044</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34959328/\">https://pubmed.ncbi.nlm.nih.gov/34959328</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J04AB30;
